Parkinson's disease drug development

For the 93 percent of early-stage Parkinson's patients who took AbbVie’s newly approved drug JUVMO for 85 weeks during clinical trials, the result was measured in preserved baseline control: they did not need to increase their standard levodopa dose. On Monday, the U.S. Food and Drug Administration officially approved the once-daily tablet, marking the first time in decades that an entirely new class of medication has been authorized to treat the progressive neurological disorder.[2][5]

Marketed as JUVMO and known clinically as tavapadon, the drug is the first selective D1/D5 receptor partial agonist. While older dopamine agonists broadly target the brain's D2 and D3 receptors—a scattershot approach that often triggers severe side effects like sudden sleep episodes and impulse control disorders—tavapadon selectively binds only to the D1 and D5 receptors. "The approval of JUVMO marks the first dopaminergic breakthrough for Parkinson's disease in decades," said Dr. Roopal Thakkar, AbbVie's chief scientific officer.[1][4][5]

The distinction in receptor targeting addresses a longstanding dilemma in neurology. For decades, patients and clinicians have faced a difficult tradeoff: rely heavily on levodopa, which effectively controls tremors but eventually causes severe involuntary movements known as dyskinesia, or use D2/D3 dopamine agonists to delay levodopa use, risking behavioral changes and extreme fatigue. By isolating the D1 and D5 pathways, JUVMO aims to maintain the motor benefits of dopamine stimulation while bypassing the neural circuits responsible for the most disruptive tolerability issues.[1][4][5]

The FDA's authorization rests on data from the comprehensive Phase 3 TEMPO clinical trial program, which evaluated the drug across the disease's entire continuum. Researchers tested tavapadon both as a standalone monotherapy for recently diagnosed patients who had not yet started levodopa, and as an adjunctive therapy for advanced patients who were already experiencing motor fluctuations on standard treatments.[1][5]

In the early-stage TEMPO-1 trial, patients taking a 15-milligram daily dose saw their combined motor and daily-living impairment scores drop by 1.7 points over 26 weeks, compared to a 0.9-point worsening in the placebo group. A parallel TEMPO-2 study confirmed these primary endpoints, with the drug delivering a placebo-adjusted improvement of roughly 9 to 12 points on standard clinical rating scales across the fixed and flexible dosing regimens.[5]

For patients further along in the disease's progression, the TEMPO-3 trial demonstrated the drug's utility as a stabilizing agent. Patients taking JUVMO alongside their existing levodopa regimen gained approximately 1 hour of "on" time—periods where their symptoms were well controlled without troublesome dyskinesia—compared to the placebo group. This stabilizing effect allowed the vast majority of trial participants to avoid escalating their levodopa doses during the 85-week open-label extension period.[1][5]

AI

However, the medication is not without its own adverse profile, and the FDA label includes specific safety warnings. Clinical trial data indicates that JUVMO can cause low blood pressure, nausea, fatigue, dry mouth, and in some cases, hallucinations or uncontrolled sudden movements. While the targeted D1/D5 approach theoretically reduces the risk of impulse control disorders seen with older agonists, long-term real-world data will be required to confirm whether those severe behavioral side effects are truly eliminated or merely reduced.[4][5]

The approval represents a critical regulatory victory for AbbVie, which acquired tavapadon through its $8.7 billion buyout of Cerevel Therapeutics in 2024. The company expects to make JUVMO available to U.S. patients in October 2026. The drug will be distributed in 5-milligram, 10-milligram, and 15-milligram tablets, alongside a specialized titration pack designed to help patients gradually build up to a therapeutic dose over their first weeks of treatment.[1][3][5]